Clonazepam: a review of open clinical trials.
Data were collected on 50 patients with panic attacks who were treated with clonazepam to determine the drug's antipanic efficacy. At a mean duration of 54.3 weeks, 62% of the patients remained in treatment and 38% were lost to follow-up. Of those remaining in treatment, 90% had a good response to clonazepam and 10% a poor response. The author concludes that clonazepam demonstrated antipanic efficacy, that the development of tolerance or abuse was not a problem, and that most of the patients are being effectively maintained at 2-3 mg/day of clonazepam.
Pollack
M H
MH
Clinical Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114.
D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D002986:Clinical Trials as Topic; D002998:Clonazepam / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010200:Panic
D002998:Clonazepam